Page 19 - Journal of Structural Heart Disease Volume 2, Issue 1

13
28. Ailawadi G1, Gerdisch MW, Harvey RL,
Hooker RL, Damiano RJ Jr, Salamon T, et al. Exclusion of the left atrial append- age with a novel device: early results of a multicenter trial. J Thorac Cardiovasc Surg. 2011;142(5):1002-1009. DOI: 10.1016/j. jtcvs.2011.07.052
29. Slater AD, Tatooles AJ, Co ey A, Pappas PS, Bresticker M, Greason K, et al. Prospective clinical study of a novel left atrial append- age occlusion device. Ann Thorac Surg. 2012; 93:1887-1889. DOI: 10.1016/j.atho- racsur.2011.12.077
30. Benussi S, Mazzone P, Maccabelli G, Ver- gara P, Grimaldi A, Pozzoli A, et al. Tho- racoscopic appendage exclusion with an AtriClip device as a solo treatment for focal atrial tachycardia. Circulation. 2011;123:1575-1578. DOI: 10.1161/CIRCU- LATIONAHA.110.005652
31. Sievert H, Lesh M, Trepels T, Omran H, Bartorelli A, Della Bella P, et al. Percutaneous left atrial appendage transcatheter occlu- sion to prevent stroke in high-risk patients with atrial brillation: Early clinical experi- ence. Circulation. 2002;105:1887-1889. DOI: 10.1161/01.CIR.0000015698.54752.6D
32. Block PC, Burstein S, Casale PN, Kramer PH, Teirstein P, Williams DO, et al. Percutaneous left atrial appendage occlusion for patients in atrial brillation suboptimal for warfa- rin therapy: 5-Year results of the PLAATO (Percutaneous Left Atrial Appendage Tran- scatheter Occlusion) study. J Am Coll Car- diol Interv. 2009;2:594-600. DOI: 10.1016/j. jcin.2009.05.005
33. Bayard Y, Omran H, Kramer P, Matthews R, Reisman M, Block P, et al. Worldwide experience of percutaneous left atrial ap- pendage transcatheter occlusion (PLAA- TO). J Neurol Sci. 2005;238:S70-S70. DOI: 10.1016/S0022-510X(05)80271-0
34. Park JW, Bethencour A, Sievert H, Santoro G, Meier B, Walsh K, et al. Left atrial ap- pendage closure with Amplatzer cardiac plug in AF. Initial European experience. Catheter Cardiovasc Interv. 2011;77:700- 706. DOI: 10.1002/ccd.22764
35. Lam YY, Yip W, Yu CM, et al. Left atrial ap- pendage closure with AMPLATZER cardiac plug for stroke prevention in atrial brilla- tion: initial Asia-Paci c experience. Cath- eter Cardiovasc Interv. 2012;79:794-780. DOI: 10.1002/ccd.23136
36. Urena M, Rodés-Cabau J, Freixa X, Saw J, Webb JG, Freeman M, et al. Percutaneous Left Atrial Appendage Closure With the AMPLATZER Cardiac plug device in pa- tients with nonvalvular atrial brillation and contraindications to anticoagula-
tion therapy. J Am Coll Cardiol. 2013;62:
96-102. DOI: 10.1016/j.jacc.2013.02.089 37. Cruz-Gonzalez I, Moreiras J, Garcia E. Throm- bus formation after left atrial appendage exclusion using an Amplatzer cardiac plug device. Catheter Cardiovasc Interv. 2011;78:
970-973. DOI: 10.1002/ccd.23126
38. Cardona L, Galrinho A, Luisa B, Leal A, An- tonio F, Lidia S, Cruz F. Thrombus formation on a left atrial appendage closure device. Circulation. 2011; 124:1595-1596. DOI:
10.1161/CIRCULATIONAHA.110.004135
39. Plicht B, Konorza TFM, Kahlert P, Al-Rashid F, Kaelsch H, Jánosi RA, et al. Risk factors for thrombus formation on the amplatzer cardiac plug after left atrial appendage occlusion. J Am Coll Cardiol Intv. 2013; 6:606-613. DOI: 10.1016/j.jcin.2013.02.014
40. Freixa X, Chan JL, Tzikas A, Garceau P, Bas- madjian A, Ibrahim R. The Amplatzer TM Cardiac Plug 2 for left atrial appendage occlusion: novel features and rst-in-man experience. EuroIntervention. 2013;8: 1094-1098. DOI: 10.4244/EIJV8I9A167
41. AMPLATZER cardiac plug clinical tri- al. Available at: http://clinicaltrials.gov/ ct2/show/record/NCT01118299?ter- m=LAA+ACP&rank=3
42. Holmes DR, Reddy VY, Turi ZG, Soshi SK, Sievert H, Buchbinder M, et al. Percutane- ous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial brillation: A randomized non-inferiority trial. Lancet. 2009;374: 534-542. DOI: 10.1016/S0140- 6736(09)61343-X
43. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classi cation schemes for predicting stroke. Results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285:2864-2870. DOI: 10.1001/ jama.285.22.2864
44. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, et al. Percutaneous left atri- al appendage closure for stroke prophylaxis in patients with atrial brillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial. Circulation. 2013; 127:720-729. DOI: 10.1161/CIRCULATIONAHA.112.114389
45. Reddy VY. Long term results of PROTECT AF: The mortality e ects of left atrial ap- pendage closure versus warfarin for stroke prophylaxis in AF. Paper presented at: Heart Rhythm Society Scienti c Sessions; May 8-11, 2013; Denver, CO.
46. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atri- al appendage closure: Results from the
Review Article
Watchman left atrial appendage sys- tem for embolic protection in patients with AF (PROTECT AF) clinical trial and continued access registry. Circulation. 2011;123:417-424. DOI: 10.1161/CIRCU- LATIONAHA.110.976449
47. Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. The prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial brillation versus long-term warfarin therapy (The PREVAIL trial). J Am Coll Cardiol. 2014; 64: 1-12. DOI: 10.1016/j.jacc.2014.04.029
48. Reddy VY, Möbius-Winkler S, Neuzil P, Schuler G, Wiebe J, Sick P, et al. Left atrial appendage closure with the WATCHMAN device in patients with a contraindica- tion for oral anticoagulation: The ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61: 2551-2556. DOI: 10.1016/j.jacc.2013.03.035
49. Bartus K, Han FT, Bednarek J, Myc J, Kapelak B, Sadowski J, et al. Percutaneous left atri- al appendage suture ligation using the lariat device in patients with atrial brilla- tion: Initial clinical experience. J Am Coll Cardiol. 2013;62:108-118. DOI: 10.1016/j. jacc.2012.06.046
50. Price MJ, Gibson DN, Yakubov SJ, Schul- tz JC, Di Biase L, Natale A, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: Results from the U.S. Transcatheter LAA Ligation Consortium. J Am Coll Cardiol. 2014;64: 565-572. DOI: 10.1016/j.jacc.2014.03.057
51. Giedrimas E, Lin AC, Knight BP. Left atri- al thrombus after appendage closure using LARIAT. Circ Arrhythm Electrophysi- ol. 2013;6:e52-e53. DOI: 10.1161/CIR- CEP.113.000532
52. Briceno DF, Fernando RJ, Laing ST. Left atri- al appendage thrombus post LARIAT clo- sure. Heart Rhythm. 2014;11:1600-1601. DOI: 10.1016/j.hrthm.2013.10.053
53. Camm AJ, Lip GY, De Caterina R, Savelle- va I, Atar D, Hohnloser SH, et al. 2012 fo- cused update of the ESC Guidelines for the management of atrial brillation: an update of the 2010 ESC Guidelines for the management of atrial brillation. Devel- oped with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747. DOI: 10.1093/ eurheartj/ehs253
54. January CT, WAnn LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, et al. 2014 AHA/ ACC/HRS Guideline for the management of patients with atrial brillation: A report of the American College of Cardiology/
Sánchez, J.M. et al.
Where Do We Stand Now?